Dosing Errors With Cubist Antibiotic Prompt FDA Warning
The FDA has issued a warning to health care professionals about the risk for dosing errors with the antibacterial drug combination ceftolozane/tazobactam (Zerbaxa, Cubist) due to confusion about the drug strength displayed on the vial and carton labeling.
Zerbaxa is a combination product consisting of ceftolozane, a cephalosporin antibacterial drug, and tazobactam, an inhibitor of certain ß-lactamase enzymes. Zerbaxa’s vial label was approved initially with a strength that reflects each individual active ingredient (1 g/0.5 g); however, the product is dosed based on the sum of these ingredients (1.5 g).
Help employers find you! Check out all the jobs and post your resume.
Zerbaxa is a combination product consisting of ceftolozane, a cephalosporin antibacterial drug, and tazobactam, an inhibitor of certain ß-lactamase enzymes. Zerbaxa’s vial label was approved initially with a strength that reflects each individual active ingredient (1 g/0.5 g); however, the product is dosed based on the sum of these ingredients (1.5 g).
Help employers find you! Check out all the jobs and post your resume.